Efficacy and safety of entrectinib▼ in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

Entrectinib▼ is a tyrosine kinase inihbitor approved globally for the treatment of NTRK fusion-positive solid tumours, based on the results of three phase 1/2 trials (ALKA-372-001; STARTRK-1; STARTRK-2). Updated results (enrolment cut-off: 31 Jul 2019; clinical cut-off 31 Aug 2020) are presented.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.